A Study of Omega-3 as a Treatment for Major Depression
Major Depression, Dysthymia
About this trial
This is an interventional treatment trial for Major Depression focused on measuring Mood Disorder
Eligibility Criteria
Inclusion Criteria: Must meet DSM IV criteria for non-psychotic major depression lasting at least 6 weeks or dysthymia. Must be under the care of a mental health practitioner. Must be able to give informed consent. Must be able to attend the Black Dog Institute. Exclusion Criteria: Unsuccessful treatment with more than 2 antidepressant medications (at therapeutically adequate doses and duration. History of psychosis or mania/hypomania or personality disorder. Non-English speaking or otherwise unable to provide historical information. Having taken Omega-3 dietary supplements in the last 3 months. Taking antidepressant medication for depression. History of allergy to n-3 PUFA supplements, finfish or shellfish. Pregnancy, breast feeding or planning to become pregnant during course of study. Post-natal depression. Current drug or alcohol abuse or dependence or history of abuse or dependence over the last 12 months. Unstable thyroid function Hepatic or renal impairment or other medical conditions that may interfere with the absorption and metabolism of omega-3 polyunsaturated fatty acids. Coagulopathy or anticoagulant treatment. Patients who, in the investigator's judgment pose a current serious suicidal or other safety risk, or patients who are not likely to be able to comply with the study protocol.
Sites / Locations
- The University of New South Wales/ Black Dog InstituteRecruiting